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Abstract
Overexpression of EGFR and versican has been reported in association with breast cancers. Considered oncogenic, these
molecules may be attractive therapeutic targets. Possessing anti-apoptotic and drug resistant properties, overexpression of
these molecules is accompanied by selective sensitization to the process of apoptosis. In this study, we exogenously
expressed a versican G3 construct in breast cancer cell lines and analyzed the effects of G3 on cell viability in fetal bovine
serum free conditioned media and evaluated the effects of apoptotic agent C2-ceramide, and chemotherapeutic agents
including Docetaxel, Doxorubicin, and Epirubicin. Versican G3 domain enhanced tumor cell resistance to apoptosis when
cultured in serum free medium, Doxorubicin, or Epirubicin by up-regulating pERK and GSK-3b (S9P). However, it could be
prevented by selective EGFR inhibitor AG 1478 and selective MEK inhibitor PD 98059. Both AG 1478 and PD 98059 enhanced
expression of pSAPK/JNK, while selective JNK inhibitor SP 600125 enhanced expression of GSK-3b (S9P). Versican G3
promoted cell apoptosis induced by C2-ceramide or Docetaxel by enhancing expression of pSAPK/JNK and decreasing
expression of GSK-3b (S9P), an observation blocked by AG 1478 or SP 6000125. Inhibition of endogenous versican
expression by siRNA or reduction of versican G3’s expression by linking G3 with 39UTR prevented G3 modulated cell
apoptosis. The dual roles of G3 in modulating breast cancer cell resistance to chemotherapeutic agents may in part explain
a potential mechanism for breast cancer cell resistance to chemotherapy and EGFR therapy. The apoptotic effects of
chemotherapeutics depend upon the activation and balance of down stream signals in the EGFR pathway. GSK-3b (S9P)
appears to function as a key checkpoint in this balance of apoptosis and anti-apoptosis. Investigation and potential
consideration of targeting GSK-3b (S9P) merits further study.
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Introduction
Chemotherapeutic drugs exhibit varied selectivity for tumour
cells dependent on cell origins and are capable of inducing tumour
cell death [1,2]. Additionally many of the commonly used
chemotherapeutic drugs also appear to influence cellular signaling
pathways that induce apoptosis in susceptible cancer cells [1,3].
Apoptosis seems to be one of the major physiologic safeguards
against uncontrolled proliferation [4]. Growth and apoptosis are
two diametrically opposed biological processes that ensure that
multi-cellular organisms can cope with the normal physiologic yet
mutagenic environment that generates millions of potential cancer
cells every day [5]. With its effects on tumor cell proliferation and
migration, versican has been shown to increase the resistance of
cancer cells to apoptosis [6]. Our previous research demonstrated
that versican appeared to confer cell resistance to apoptosis
following treatment with low serum medium or hydrogen peroxide
[7,8]. The combination of selective apoptotic resistance and
sensitivity has been reported in overexpression of the V1 versican
isoform [7]; the intimate relationship between proliferation and
apoptosis cannot be separated and cancer cells often express either
hypersensitivity or resistance to apoptosis that is dependent upon
tissue conditions.
As a member of the large aggregating chondroitin sulfate
proteoglycan family, versican is structurally composed of a N-
terminal G1 domain, a glycosaminoglycan (GAG) attachment
region, and a C terminus (or G3) selectin-like domain [9,10]. The
G3 domain interacts with different ECM proteins [11] and binds to
certain cell surface proteins including epidermal growth factor
receptor (EGFR) [12,13]. Extracellular versican has been observed
to be elevated in a variety of human tumors including breast
carcinoma [14,15,16]. High expression has been observed in the
interstitial tissues at the invasive margins of breast carcinoma and
appears prognositic being predictive of cancer relapse in patients
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of versican G3 domain does not only appear to enhance breast
cancer cell proliferation in vitro and in the mammary gland, but also
promotes tumor cell migration in vitro and systemic metastasis in
syngenetic orthotopic models in vivo [19,20].
Increased expression of EGFR occurs frequently in human
breast cancer and is associated with a poor prognosis [21]. Anti-
apoptotic and drug resistant effects have been implicated in EGFR
signaling. Some molecules in the pathway, however, may promote
cell cycle arrest and enhanced sensitivity to chemotherapeutic
drugs [22]. Direct targeting of EGFR is a promising therapeutic
strategy for breast cancers with abnormalities in this pathway and
may be beneficial in breast cancer patients who cannot tolerate
surgery or traditional chemotherapy, or in advanced recalcitrant
cases with poor prognoses [23,24].
There is a desire to improve our understanding of the cellular
mechanisms involved in versican G3 mediated tumor growth and
invasiveness. Understanding EGFR signaling that influences cell
sensitivity to apoptosis as well as effects that are elicited by
chemotherapy may help guide our understanding towards
identifying other potential target molecules in the pathway from
an immunotherapeutic perspective. To investigate the effects of
versican G3 domain on breast cancer cell apoptosis, we
exogenously expressed versican G3 in mouse mammary tumor
cell lines 66c14, 4T07, 4T1 [25], and human breast cancer cell
lines MT1, MDA-MB-231, MCF-7, MDA-MB-468. We evaluated
the effect of apoptotic agent C2-ceramide as well as chemother-
apeutic drugs such as Doxorubicin, Epirubicin, and Docetaxil on
cell activity and EGFR downstream signaling.
Materials and Methods
Materials and cell cultures
The monoclonal antibodies against ERK2, pERK, CDK2, and
Caspase-3 were obtained from Santa Cruz Biotechnology. The
polyclonal antibodies against SAPK/JNK and pSAPK/JNK were
obtained from Cell Signaling. EGF, selective EGFR inhibitor AG
1478, selective MEK inhibitor PD 98059, selective SAPK/JNK
inhibitor SP 600125, hydroxyurea, and the monoclonal antibody
against b-actin used in the study were obtained from Sigma.
Glycogen synthase kinase-3ß serine-9 phosphorylation (GSK-3b,
S9P), and polyclonal antibodies against versican V1 were obtained
from Abcam. Horseradish peroxidase-conjugated goat anti-mouse
IgG and horseradish peroxidase-conjugated goat anti-rabbit IgG
were obtained from Bio-Rad. Immunoblotting was performed
using the ECL Western blot detection kit. Cell Proliferation
Reagent WST-1 was obtained from Roche Applied Science.
Mouse mammary tumor cell lines 67NR, 66c14, 4T07, 4T1
[26], and human breast cancer cell line MDA-MB-231 were
cultured in DMEM media[27], and human breast cancer cell line
MT-1 [28], MCF-7 [29], MDA-MB-468 were cultured in RPMI-
1640 media [30], which were supplemented with 10% fetal calf
serum, penicillin (100 U/ml) and streptomycin (100 mg/ml) and
maintained at 37uC in a humidified atmosphere of 5% CO2.I n
selected experiments, cell suspensions were cultured with EGF
(20 ng/ml), EGFR inhibitor AG 1478 (2.0 mM), selective MEK
inhibitor PD 98059 (50 mM), and selective SAPK/JNK inhibitor
SP 600125 (100 nM).
The pcDNA1 - G3 construct and pcDNA1 - G3 fragment
lacking the EGF-like motifs (G3DEGF) construct were generated
by us [31,32,33]. Mouse mammary tumor cell lines 66c14, 4T07,
4T1 and human breast cancer cell line MT-1, MDA-MB-231,
MCF-7, and MDA-MB-468 cells were transfected with pcDNA1-
vecor and G3 constructs. The 66c14 cells were transiently
transfected with G3 construct, G3DEGF construct, or the control
vector. A leading sequence that has been shown to be efficient in
product secretion was engineered to both construct by us
previously [32,34,35].
Cell viability assays
G3 and vector-transfected 66c14 cells (2610
5) were cultured in
10% FBS/DMEM medium in culture dishes and maintained at
37uC for 12 hours. After cell attachment, we changed the medium
to serum free DMEM medium or 10% FBS/DMEM medium
which contained different concentrations of chemotherapeutic
compounds. Cells were harvested daily and cell number was
analyzed by Coulter Counter. Cell survival assays were also
performed with colorimetric proliferation assays (Cell Proliferation
Reagent WST-1). Versican G3 and control vector transfected
breast cancer cells (1610
4 cells/well) were inoculated and cultured
in 10% FBS/DMEM medium in 96 well culture dishes for
12 hours. After cell attachment, we changed the medium into
serum free DMEM medium or 10% FBS/DMEM medium
containing different concentrations of chemotherapeutic agents,
and then cultured cells with 10 ml WST-1 reagent for 4 hours. The
absorbance of the samples against a background blank control was
measured by a microplate reader.
Western blot analysis
Protein samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on separating gel
containing 7–10% acrylamide. Separated proteins were trans-
blotted onto a nitrocellulose membrane in 16Tris/glycine buffer
containing 20% methanol at 60 V for 2 h in a cold room. The
membrane was blocked in TBST (10 mM Tris-Cl, pH 8.0,
150 mM NaCl, 0.05% Tween 20) containing 5% non-fat dry
milk powder (TBSTM) for 1 hour at room temperature, and then
incubated with primary antibodies at 4uC overnight. The
membranes were washed with TBST (3630 minutes) and then
incubated with appropriate horseradish peroxidase-conjugated
secondary antibodies in TBSTM for 1 hour. After washing as
described above, the bound antibodies were visualized with an
ECL detection kit as described previously [36,37].
Cell cycle analysis
The expression of cell cycle-related proteins was analyzed by
immunoblotting probed with appropriate antibodies as described
above. G3- and vector-transfected 66c14 cell lines were cultured in
10% FBS/DMEM media at 37uC, 5% CO2 with or without
EGFR inhibitor AG 1478 (0.2, 2.0, and 5.0 mM), and selective
MEK inhibitor PD 98059 (20, 50, and 100 mM). The cells were
washed and resuspended in cold PBS and incubated in ice-cold
70% ethanol for 3 hours. The cells were then centrifuged at
1,500 rpm for 10 minutes and resuspended in propidium iodide
(PI) master mix (40 mg/ml PI and 100 mg/ml RNase in PBS) at a
density of 5610
5/ml and incubated at 37uC for 30 minutes before
analysis by flow cytometry.
Annexin V assays
An Annexin V-FITC apoptosis detection kit (Biovision Inc,
Mountain View, CA, USA) was used to detect apoptotic activity.
Cells (1610
6) were collected and resuspended in binding buffer,
and Annexin V-FITC and propidium iodide were added to each
sample and incubated in the dark for 5 minutes. Annexin V-FITC
binding was determined by flow cytometry (Ex=488 nm;
Em=530 nm) using FITC signal detector (FL1) and propidium
staining by the phycoerythrin emission signal detector (FL2).
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6 cells were harvested, and total RNA was extracted with
the Qiagen RNeasy mini kit. Two micrograms of total RNA were
used to synthesize cDNA, a portion of which (equal to 0.2 mg
RNA) was used in a PCR with two appropriate primers. PCR
products were analyzed on agarose gel and detected using
ethidium bromide staining as previously described [38,39].
Results
Versican G3 domain enhanced tumor cell survival in
serum free medium by up-regulating pERK and GSK-3b
(S9P)
A greater viability in low serum and serum-free conditions in the
presence of versican G3 was observed in human breast cancer cells
[19]. To investigate the expression of versican G3 domain on
breast cancer cell survival, G3-transfected or vector-transfected
66c14 cells were cultured in serum free DMEM medium. G3
transfected cells grew faster than vector cells in the initial 4 days.
After 4 days, a great number of vector cells floated in the medium,
while the G3 transfected cells appeared well attached (Fig. 1a).
Annexin V assays confirmed that cell death occurred through
apoptosis (Fig. 1b). G3-transfected 66c14 cells showed a greater
viability during 14 days of culture in serum free medium (Fig. 1c).
Versican G3 domain enhanced mouse breast cancer cell line
66c14, 4T07 and human breast cancer cell line MT1 and MDA-
MB-468 survival in serum free medium (Fig. 1d). However
expression of G3 in 4T1 cell line, which is demonstrated to have
high levels of endogeneous versican [20], didn’t change the cell
proliferation significantly. Flow cytometer confirmed that the
percentage of cells in S, G2 and M stages were much higher in G3-
transfected cells than in vector cells (Fig. 1e). Immunoblotting
indicated that versican G3 enhanced cell survival in serum free
medium by increasing expression of pERK, GSK-3b (S9P) and
CDK2 (Fig. 2a). Versican G3 enhanced cell survival could be
prevented by selective EGFR inhibitor AG 1478 and selective
MEK (ERK kinase) inhibitor PD 98059 (Fig. 2b). Immunoblotting
showed that both AG 1478 and PD 98059 enhanced expression of
pSAPK/JNK in G3 expressing cells, and partly prevented G3
enhanced expression of pERK. Whereas only PD 98059 blocked
G3 enhanced expression of GSK-3b (S9P) (Fig. 2c). Selective JNK
inhibitor SP 600125 enhanced expression of GSK-3b (S9P).
Versican G3 enhanced breast cancer cell apoptosis
induced by C2-ceramide through expression of pSAPK/
JNK and caspase-3
66c14 cells expressing versican G3 demonstrated lower cell
viability compared with vector control groups when cultured in
C2-ceramide (Fig. 3a, 3c, 3d). Annexin V assays confirmed that
cell death occurred through apoptosis (Fig. 3b). C2-ceramide is a
synthetic lipid, a potent apoptosis inducing substance that has been
described as a second messenger of TNF and other stimuli.
Immunoblotting showed that the G3 construct enhanced tumor
cell apoptosis induced by C2-ceramide through expressing high
levels of pSAPK/JNK and caspase-3 (Fig. 3e). During this
procedure, G3-transfected cells expressed high level of pERK
(Fig. 3e). Lower cell viability was also recorded in G3-expressing
MT-1, MDA-MB-468, 4T07, and 4T1 cells after treatment with
C2-ceramide (no significance in 4T1 cell line, Fig. 4a). To
investigate whether versican G3 promotes cell apoptosis through
the EGFR/JNK pathway, we cultured the G3- and vector-
transfected 66c14 cells with C2-ceramide, EGF, AG 1478, PD
98059, or SP 600125. We found that versican G3 enhanced cell
apoptosis induced by C2-ceramide, an observation inhibited by
EGFR inhibitor AG 1478 and SAPK/JNK inhibitor SP 600125
(Fig. 4b). During treatment with C2-ceramide, G3-transfected cells
expressed increased pSAPK/JNK and caspase-3, which were also
induced by EGF, findings blocked by AG 1478 and SP 600125 but
not by PD 98059 (Fig. 4c). SP 600125 also enhanced G3
transfected cells expression of GSK-3b (S9P) when treated with
C2-ceramide (Fig. 4c).
Versican G3 modulated effects on breast cancer cell
apoptosis induced by chemotherapeutic agents through
the activation of EGFR related signaling
In order to investigate the effects of versican G3 domain on
breast cancer cell apoptosis induced by chemotherapeutic drugs,
we chose 5 frequently used compounds. Docetaxel is a clinically
well established anti-mitotic chemotherapy medication used
mainly for the treatment of breast, ovarian, and non-small cell
lung cancer [40,41]. Doxorubicin and Epirubicin are anthracy-
cline antibiotics and work through intercalating DNA strands that
result in complex formation that inhibits DNA and RNA synthesis.
They also trigger DNA cleavage by topoisomerase II, resulting in
mechanisms that lead to cell death. Both agents are commonly
used in the treatment of a wide range of cancers [42].
Cyclophosphamide, a nitrogen mustard alkylating agent, from
the oxazophorines group [43] was also evaluated. Finally,
Trastuzumab is a humanized monoclonal antibody that acts on
the HER2/neu receptor and is used principally as an anti-cancer
therapy in breast cancer patients whose tumors overexpress this
receptor [44].
Analysis by light microscopy revealed that G3-transfected 4T07
cells showed increased cell apoptosis induced by Docetaxel,
however, there was a reduction in cell apoptosis when treated
with Doxorubicin, or Epirubicin. There was no appreciable
difference between G3-transfected cells and the vector- cells after
they were treated with Cyclophosphamide or Trastuzumab
(Fig. 5a). Annexin V apoptosis assays confirmed that apoptosis
was enhanced in G3 expressing cells when treated with Docetaxel,
while apoptosis decreased when cultured with Doxorubicin and
Epirubicin. WST-1 assays showed that versican G3- transfected
MT-1, MDA-MB-468, 66c14, 4T07 cells expressed lower viability
when treated with Docetaxel while higher viability was observed
when cells were cultured in Doxorubicin and Epirubicin (Fig. 6a,
6b, 6c). However there is no significance for 4T1 cells when
treated with Docetaxel, and also no significance for MDA-MB-468
when treated with Doxorubicin. The expression of endogenous
versican probably makes the effect of function of exogenously
expression of versican G3 not so obviously. Higher expression of
versican in 4T1 cell line than other three mouse breast cancer cell
lines supports above explanation [20]. MDA-MB-468, a human
breast cancer cell line with a very high number of EGF receptors
[45], shows less EGFR enhanced when trasfected with versican G3
domain. This may be the main reason why the G3 expressing
MDA-MB-468 shows less chemical sensitivity to chemicals.
Immunoblotting showed that G3-expressing cells increased p-
ERK expression in the chemically treated and non-treated
samples. When treated with C2-ceramide or Docetaxel, G3-
expressing cells expressed a dramatically high level of pSAPK/
JNK, while Doxorubicin and Epirubicin did not significantly
impact expression of pSAPK/JNK in G3-expressing cells (Fig. 6d).
WST-1 Cell Survival Assays showed that versican G3 enhanced
cell apoptosis induced by Docetaxel, an observation blocked by
AG 1478 and SP 6000125 (Fig. 6e); it was also observed that cell
apoptosis decreased in the presence of Doxorubicin, a finding
blocked by AG 1478 and PD 98059 (Fig. 6f).
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(or by linking G3 domain with 39UTR) prevented G3
modulated effects on cell apoptosis induced by
chemotherapeutic drugs
The key functions of the EGF-like motifs of versican G3
domain were well demonstrated by our former study
[31,32,46]. Here we found that G3 fragment lacking the
EGF-like motifs (G3DEGF) construct transfected 4T07 cells
did not show enhanced cell apoptosis when treated with C2-
ceramide or Docetaxel, and also did not show enhanced anti-
apoptosis when cultured in Doxorubicin or Epirubicin as G3
transfected cells (Fig. 7a, 7b). Immunoblotting indicated that
G3DEGF expressing cells did not showed enhanced pERK as
G3 expressing cells. G3DEGF expressing cells also did not
showed enhanced pJNK when treated with Docetaxel and
enhanced GSK-3b(S9P) when cultured in Doxorubicin as G3
expressing cells.
Figure 1. Versican G3 domain enhanced tumor cell survival in serum free medium. a) G3-transfected and vector-transfected 66c14 (2610
5)
were cultured in 10% FBS/DMEM medium in culture dishes for 12 hours. After cell attachment, we changed the medium to serum free DMEM and
cultured cells for 6 days. Cell viability was analyzed by light microscopy. b) After culturing in serum free medium for 2 days, cells were analyzed with
Annexin V and propidium iodide staining using flow cytometry. Annexin V and propidium iodide assays confirmed that cell death was apoptosis. c)
G3- and vector-transfected 66c14 (2610
5) were cultured in 10% FBS/DMEM medium in culture dishes for 12 hours. After cell attachment, we changed
the medium into serum free DMEM medium and cultured them for 14 days. Cells were harvested and counted under light microscopy every 2 days.
Experimental results are compared with vector control group, n=6,*p,0.05, **p,0.01, analyzed with t-test. d) 1610
4 G3- and vector-transfected
human breast cancer cells MT-1 and MDA-MB-468, mouse mammary tumor cells 66c14, 4T07, and 4T1 were inoculated and cultured in 10% FBS/
DMEM medium in 96 well culture dishes for 12 hours. After cell attachment, we changed the medium to serum free DMEM and cultured them for 8
days. WST-1 Cell Survival Assays were used to test cell viability. Compared with vector control group, n=6,*p,0.05, **p,0.01, analyzed with t-test.
e) Cell cycles were analyzed by flow cytometer. Compared with vector control group, n=4,*p,0.05, **p,0.01, analyzed with t-test.
doi:10.1371/journal.pone.0026396.g001
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expressed differently in the four human breast cell lines. It was
expressed highly in MT-1, MDA-MB231 and MDA-MB-468 cells,
and low levels were observed in MCF-7 cells (Fig S1a). The anti-
versican siRNA that has been confirmed to be able to silence
vesicant expression [47] was used to transfect MT-1 cells, and it
revealed significant versican V1 mRNA and protein down-
regulation through RT-PCR and immunoblotting (Fig S1b). The
Figure 2. Versican G3 domain enhanced tumor cell survival in serum free medium by up-regulating pERK. a) G3- and vector-
transfected 66c14 (2610
5)2 610
5 were cultured in 10% FBS/DMEM medium in culture dishes for 12 hours. After cell attachment, we changed the
medium to serum free DMEM and cultured them for 6 days. Cell lysates were prepared and subjected to immunoblotting with antibodies to ERK2,
pERK, GSK-3b (S9P), GSK-3b, CDK2, CDK6, CDC2P34, and b-actin. b) G3-transfected and vector-transfected 66c14 cells (1610
4) were inoculated and
cultured in 10% FBS/DMEM medium in 96 well culture dishes for 12 hours. After cell attachment, we changed the medium to serum free DMEM, with
EGF (20 ng/ml), selective EGFR inhibitor AG 1478 (2.0 mM), selective MEK (ERK kinase) inhibitor PD 98059 (50 mM), or selective JNK inhibitor SP 600125
(100 nM) cultured for 6 days with medium changed every 2 days. WST-1 Cell Survival Assays were used to analyze cell viability. Compared with vector
control group, n=6, * p,0.05, **p,0.01, analyzed with t-test. c) After culture in serum free medium for 6 days, cell lysates were prepared and
subjected to immunoblotting with antibodies to ERK2, pERK, GSK-3b (S9P), GSK-3b, and b-actin.
doi:10.1371/journal.pone.0026396.g002
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from abcam (ab19345) which is indicated suitable for detection of
versican V1 isoform, and shows only one band -versican V1, 250–
300 kDa. We then examined the expression of pERK, ERK,
pSAPK/JNK, SAPK/JNK in anti-versican siRNA expressing
MT-1 cells treated with Docetaxel, Doxorubicin, or Epirubicin.
Immunoblotting showed that the expression of pERK V1 was
down-regulated in the anti-versican siRNA expressing MT-1 cell,
irrespective of whether or not it was chemically treated, and there
was no significant change in the expression of pSAPK/JNK (Fig
Figure 3. Versican G3 enhanced cell apoptosis induced by C2-ceramide by expressing pSAPK/JNK and caspase-3. a) G3- and vector-
transfected 66c14 cells (2610
5) were inoculated in 6 well culture dishes. After cultured for 12 hours, all samples were treated with 0, 10, 40, or 80 mM
C2-ceramide for 24 hours. Analysis by light microscopy revealed that treatment with a dose of 40 or 80 mM C2-ceramide induced significant cell
death in G3-transfected cells. b) After culture in 40 mM C2-ceramide serum free medium for 4 hours, cells were analyzed with Annexin V and
propidium iodide staining using flow cytometry. Annexin V and propidium iodide assays confirmed that cell death occurred through apoptosis. c) G3-
transfected and vector-transfected 66c14 cells (1610
4) were inoculated and cultured in 10% FBS/DMEM medium in 96 well culture dishes for
12 hours. After cell attachment, all samples were treated with 0, 10, 40, or 80 mM C2-ceramide for 24 hours. Lower cell viability was observed for the
G3 experimental group as compared with the control group. Compared with vector control group, n=6,*p,0.05, **p,0.01, analyzed with t-test. d)
Cells were also treated with 40 mM C2-ceramide for 6, 12, 24 hours. WST-1 assays were performed. Compared with vector control group, n=6,
* p,0.05, **p,0.01, analyzed with t-test. e) Cells were also treated with 40 mM C2-ceramide for 6 hours, harvested and subjected to immunoblotting
with antibodies to pSAPK/JNK, SAPK/JNK, ERK2, pERK, Caspase-3, and b-actin.
doi:10.1371/journal.pone.0026396.g003
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apoptosis induced by C2-ceramide and Docetaxel, whereas cell
apoptosis induced by Doxorubicin and Epirubicin was reduced.
While the anti-versican siRNA- transfected cells showed a
reduction in the extent of cell apoptosis induced by C2-ceramide,
we observed enhanced effects on cell apoptosis induced by
Doxorubicin and Epirubicin when compared with G3-transfected
and vector-transfected cells (Fig S1d).
In order to further confirm the role of G3 in apoptosis, we
linked the G3 domain with versican 39-UTR (Fig S2a). Our
previous research indicated that G3-39 UTR transfected cells
expressed lower G3 protein compared to G3 expressing cells [48].
So we can use the G-UTR construct to observe the effect of
decreasing expression of G3 in G3 expressing cells. Immunoblot-
ting demonstrated that G3-39 UTR stably transfected 66c14 cells
expressed much lower levels of G3 protein than the G3 transfected
cells (Fig S2b). The microscopic morphology of G3 transfected
cells was quite different from the vector control cells. The G3
expressing cells spread evenly on the culture dishes, while the
vector control cells were prone to cell aggregation. The G3-39
Figure 4. Versican G3 domain enhanced tumor cell apoptosis induced by C2-ceramide by up-regulating the EGFR/JNK pathway. a)
1610
4 G3-transfected and vector-transfected MT-1, MDA-MB-468, 66c14, 4T07, and 4T1 cells were inoculated and cultured in 10% FBS/DMEM
medium in 96 well culture dishes for 12 hours. After cell attachment, cells were treated with 40 mM for 24 hours. WST-1 assays were used to analyze
cell viability. b) G3-transfected and vector-transfected 66c14 cells (1610
4) were inoculated and cultured in 10% FBS/DMEM medium in 96 well culture
dishes for 12 hours. After cell attachment, we added C2-ceramide (40 mM), and EGF (20 ng/ml), AG 1478 (2.0 mM), PD 98059 (50 mM), or SP 600125
(100 nM) cultured for 24 hours. WST-1 Cell Survival Assays were performed. Compared with vector control group, n=8,*p,0.05, **p,0.01, analyzed
with t-test. c) Treated with C2-ceramide (40 mM) and EGF (20 ng/ml), AG 1478 (2.0 mM), PD 98059 (50 mM), or SP 600125 (100 nM) for 6 hours, cells
were harvested and subjected to immunoblotting with antibodies to pSAPK/JNK, SAPK/JNK, ERK2, pERK, Caspase-3, and b-actin.
doi:10.1371/journal.pone.0026396.g004
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morphologies. G3-39 UTR- transfected cells neither promoted the
extent of cell apoptosis induced by C2-ceramide or Docetaxel, nor
enhanced cell survival when treated with Doxorubicin or
Epirubicin (Fig S2c, S2d). Our experiments demonstrate that the
sensitivity of breast cancer cells to chemotherapeutically induced
apoptosis was versican G3 domain dependant.
Discussion
Increased activation of EGFR and dysregulated expression of
versican contributes towards a more aggressive human breast
cancer phenotype [15,16,49,50,51]. Targeted therapies shows
considerable promise for the future of cancer treatment and much
attention has been focused on developing inhibitors of the EGFR-
Figure 5. Versican G3 domain enhanced breast cancer cell apoptosis induced by Docetaxel, while cell apoptosis was reduced when
treated with Doxorubicin, or Epirubicin. a) G3-transfected and vector-transfected 4T07 cells (1610
5) were inoculated in 12 well culture dishes.
After cultured for 12 hours, all samples were treated with 2 mM Docetaxel, 8 mM Doxorubicin, 10 mM Epirubicin, 15 mM Cyclophosphamide, or 30 mM
Trastuzumab for 24 hours. Cell viability was observed by light microscopy. b) After treated with 2 mM Docetaxel, 8 mM Doxorubicin, or 10 mM
Epirubicin for 2 hours, all the samples were subjected to Annexin V assays.
doi:10.1371/journal.pone.0026396.g005
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PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e26396mediated signaling pathway [49,52,53]. Evidence that EGFR
signaling promotes cell proliferation, cell survival and metastasis
supports current efforts to identify approaches that inhibit this
pathway [54,55,56]. Anti-EGFR immunotherapeutics in cancer
treatment is undergoing intensive study [57]. The efficacy of
Erlotinib and Gefitinib in treating breast cancer is currently being
tested in various phases of clinical trials either as single agent
treatment or in combination with other agents such as Docetaxel,
Gemcitabine, Paclitaxel [58,59,60]. The overall efficacy of anti-
EGFR treatments to date remains moderate and there is desire to
Figure 7. The roles of epidermal growth factor-like motifs of versican G3 domain in modulating breast cancer cell apoptosis
induced by chemotherapeutic drugs. a)1610
4 G3-, G3DEGF- and vector-transfected 4T07 were inoculated and cultured in 10% FBS/DMEM
medium in 96 well culture dishes for 12 hours. After cell attachment, cells were treated with 40 mM C2-ceramide, 2 mM Docetaxel, 8 mM Doxorubicin,
or 10 mM Epirubicin for 24 hours. Cell viability was tested by WST-1 assays. b) After treated with 2 mM Docetaxel or 8 mM Doxorubicin for 1 hour,
samples were subjected to Annexin V assays. c) Treated with 2 mM Docetaxel or 8 mM Doxorubicin all cells were processed to lysates and subjected to
immunoblotting with antibodies to pSAPK/JNK, SAPK/JNK, ERK2, pERK, GSK-3b (S9P), and b-actin.
doi:10.1371/journal.pone.0026396.g007
Figure 6. Versican G3 modulated breast cancer cell apoptosis induced by chemotherapeutic drugs through activation of EGFR
related signaling. a) 1610
4 G3- and vector-transfected MT-1, MDA-MB-468, 66c14, 4T07, and 4T1 cells were inoculated and cultured in 10% FBS/
DMEM medium in 96 well culture dishes for 12 hours. After cell attachment, cells were treated with 2 mM Docetaxel for 24 hours. Cell viability was
tested by WST-1 assays. b) All cells were treated with 8 mM Doxorubicin, and subjected to WST-1 assays. c) All cells were treated with 10 mM
Epirubicin, and subjected to WST-1 assays. Compared with vector control group, n=6, * p,0.05, **p,0.01, analyzed with t-test. d) Treated with
40 mM C2-ceramide, 2 mM Docetaxel, 8 mM Doxorubicin, 10 mM Epirubicin, 15 mM Cyclophosphamide, or 30 mM Trastuzumab for 6 hours, G3-
expressing and vector- expressing 66c14 cells were processed to lysates and subjected to immunoblotting with antibodies to pSAPK/JNK, SAPK/JNK,
ERK2, pERK, and b-actin. e) G3-transfected and vector-transfected 66c14 cells (1610
4) were inoculated and cultured in 10% FBS/DMEM medium in 96
well culture dishes for 12 hours. After cell attachment, we added Docetaxel (2 mM), and EGF (20 ng/ml), AG 1478 (2.0 mM), PD 98059 (50 mM), or SP
600125 (100 nM) cultured for 24 hours. WST-1 Cell Survival Assays were used to analyze cell viability. f) G3-transfected and vector-transfected 66c14
cells (1610
4) were also treated with Doxorubicin (8 mM), and EGF (20 ng/ml), AG 1478 (2.0 mM), PD 98059 (50 mM), or SP 600125 (100 nM) cultured for
24 hours. Cell viability was analyzed by WST-1 assays. Compared with vector control group, n=8,*p,0.05, **p,0.01, analyzed with t-test.
doi:10.1371/journal.pone.0026396.g006
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understanding of the signaling pathway [61]. A phase II study of
using Erlotinib and Gemcitabine demonstrated lower than
anticipated effects on patients with metastatic breast cancer [58]
while a Phase I study applying Gefitinib and Docetaxel
demonstrated encouraging anti-tumor activity as a first-line
chemotherapy in metastatic breast cancer [60].
Abnormal expression of proteoglycans (PGs), such as versican,
in cancer and stromal cells may serve as a biomarker for tumor
progression and patient survival [62]. Enhanced understanding of
the regulation and involvement of versican in cancer may offer a
novel approach to cancer therapy by targeting the tumor
microenvironment [62]. The effect of signaling pathways on
versican synthesis can be reversed following treatment with various
tyrosine kinase inhibitors [63]. The tyrosine kinase inhibitor
genistein can block versican expression induced by growth factors
in malignant mesothelioma cell lines [64]. Therefore, targeting
versican synthesis may be a potential mechanism for reducing this
powerful tumor-promoting agent. Genetic and preclinical studies
support the targeting of growth factor signaling as a therapeutic
strategy for combating cancer. Individuals with overexpression of
versican in breast cancer may more likely benefit from anti-EGFR
therapy given known effects of EGF-like motifs in versican, a
scientific consideration that warrants further evaluation. However,
there are no data to show that such approaches are effective in
inhibiting the effects of versican in cancer cell models.
The presence of two EGF-like domains in versican G3 and the
importance of versican as a prognostic factor in breast cancer
motivates further research in delineating the role of EGF receptors
and the downstream signaling pathways in invasive breast cancer
[19]. Versican G3 domain appears to be important in local and
systemic invasiveness of human breast cancer [19]; our previous
investigation demonstrated that versican G3 domain enhanced
breast cancer cell growth, migration and systemic metastasis by
up-regulating the EGFR-mediated signaling pathway [20]. Both
selective EGFR inhibitor AG 1478 and selective MEK inhibitor
PD 98059 were observed to be able to block this signaling pathway
and prevent versican G3 induced effects on mammary cancer cell
proliferation. In the present study, we have focused on the role of
versican G3 domain in modulating breast cancer cell apoptosis.
Breast cancer cell apoptosis appears to be a factor associated with
cancer cell sensitivity or resistance to chemotherapy and
mechanisms appear influenced by EGFR signaling. The particular
activation or inhibition of downstream EGFR signaling appears to
influence cancer cell apoptotic responses to versican mediated
effects and appear variably modulated dependant on chemother-
apeutic drug or EGFR inhibitor delivered.
It has been reported that versican and its G3 domain possess
properties that promote cell growth and survival in low serum and
serum-free conditions in breast cancer cells [19,20]. Versican has
also been described to contribute an important role in reducing
oxidant injury through an enhancement of cell-matrix interactions
[8]. Integrin-b1 was reported to reduce radical-induced apoptosis
by binding to G3 domain [65]. In the current study, we
demonstrated that versican G3-expressing breast cancer cells
express enhanced cell survival in serum free medium and in
response to certain chemotherapeutic drugs such as Doxorubicin
and Epirubicin. G3 expressing cells demonstrated a greater
viability in serum free medium and chemotherapeutic drugs such
as Doxorubicin or Epirubicin, which expressed activated EGFR/
ERK signaling. pERK, GSK-3b (S9P) and CDK2 levels were
continually recorded at high levels in G3-expressing cells. Recent
advances in the mechanisms of oncogenesis have revealed that the
constitutive activation of the EGFR/ERK pathway allows the
tumor cells to bypass regulatory check points that normally
balance cell growth and cell apoptosis thereby activating cell cycle
entry. Effective chemotherapy may induce cellular damage on a
massive scale because it can engage one or more of these check
points or drive cancer cells towards apoptosis [66]. Activation of
CDK2 and pERK, and that the bypass of regulatory controls in
cell cycle progression and cell apoptosis appear to significantly
influence tumor growth and survival [66]. Activated glycogen
synthase kinase-3ß serine-9 phosphorylation (GSK-3b, S9P) is also
required for tumor cell survival and anti-apoptosis [67]. Based on
that the present study, enhanced expression of pERK, GSK-3b
(S9P) and CDK2 in G3- expressing breast cancer cells favored cell
survival and growth even in serum free conditions or when
cultured in the environment of applied chemotherapeutic
reagents. In particular, versican G3 enhanced cell survival was
prevented by both selective EGFR inhibitor AG 1478 and
selective MEK (ERK kinase) inhibitor PD 98059 through
mechanisms blocking G3 activated expression of pERK and
GSK-3 b (S9P). Versican G3-expressing breast cancer cells
demonstrated enhanced cell survival in serum free medium and
chemotherapy by activating EGFR/ERK signaling and its down-
stream pathway proteins CDK2 and GSK-3b (S9P). To validate
the roles of versican and G3 domain in modulating breast cancer
cell apoptosis in response to applied chemotherapy, we transfected
tumor cells with anti-versican siRNA as well as by linking versican
G3 domain with versican 39-UTR (G3-UTR) that reduces
versican and G3’s functionality. Prior study demonstrated that
non-coding versican 39-UTR significantly down-regulates G3
protein expression [48]. Concordantly, we observed that both
anti-versican siRNA and G3-UTR construct reduced G3
enhanced anti-apoptosis when treated with Doxorubicin and
Epirubicin.
The EGFR signaling pathway is indispensable for cell cycle
progression while it may also efficiently enhance apoptosis [68].
Although activation of the EGFR/ERK signaling pathway is
generally considered to lead to cell survival [69], there is evidence
that in certain conditions it may also transmit pro-apoptotic signals
[69,70]. In addition to its effects on proliferative capacity and
increasing apoptotic resistance, over-expression of versican can be
accompanied by selective sensitization to apoptosis [7]. Whereas
V1-transfected cells have shown resistance to apoptosis, they also
have become significantly sensitized to other apoptotic stimuli,
including UV radiation, chemotherapeutics, hypoxic mimetics,
and conjugated linoleic acid. Elevated resting levels of the tumor
suppressor p53 play a key role in inducing apoptosis in response to
various detrimental events, including DNA damage, hypoxia, and
telomere erosion [7]. In this study we also noted that versican G3
expressing breast cancer cells showed enhanced apoptosis when
treated with certain chemicals, such as C2-ceramide and
Docetaxel. In this scenario, chemotherapy induced apoptosis
may be enhanced due to the recruitment of enhanced efficiency of
cellular signaling. We found that although high levels of pERK
were observed in G3-expressing cells when treated with these
chemicals, one of the other EGFR down-stream proteins p-
SAPK/JNK was dramatically activated. The pro-death or pro-
survival role of ERK can have both, survival or cell death activities
[22,71]. Literature supports an effect of breast cancer cells on
cellular SAPK/JNK activation in a pro-death capacity but a role
of pro-survival was also observed [72]. In our study, both p-ERK
and p-JNK was expressed in high levels in the G3-expressing cells
after treatment with C2-ceramide and Docetaxel. To determine
which factor played a key role in versican G3 enhanced cell
apoptosis, we co-treated the G3-expressing cells with chemicals
and AG 1478, PD 98059 or SP 600125; we observed that G3
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600125 but was not appreciably by PD 98059. This supports
versican G3 promotion of tumor cell apoptosis induced by C2-
ceramide and Docetaxel occurring through EGFR/JNK mediated
signaling. Persistently high levels of p-SAPK/JNK observed in G3-
expressing breast cancer cells resulted in an increase of one of the
Figure 8. Versican G3 domain modulates breast cancer cell apoptosis in response to chemotherapy and EGFR targeting therapy. a)
A model of versican G3 in modulating breast cancer cell apoptosis in chemotherapy and EGFR targeting therapy. The differential responses to
chemical induced apoptosis depend on activation and balance of EGFR signaling and its further enhanced down stream pathway. Overexpressing of
versican G3 in breast cancer cell enhances expression of EGFR signal and its downpathways. Usually it will process to ERK and GSK pathway, which
expresses enhanced cell survival. The GSK works as a key point, which inhibits expression of JNK and makes the cell process to the ERK pathway.
Expression of JNK may induce cell apoptosis. Some chemicals like c2-ceramide and Docetaxel can directly inhibit expression of GSK, which alleviates
its inhibition on JNK pathway. Expression of JNK can also inhibit expression of GSK, making the G3 expression cells process to apoptosis. b) Vector
and G3 transfected 66c14 cells (1610
6) were inoculated and cultured in 10% FBS/DMEM medium in 6 well culture dishes for 12 hours. After cell
attachment, cells were treated with serum free DMEM medium for 4 days or treated with 40 mM C2-ceramide, 2 mM Docetaxel, 8 mM Doxorubicin, or
10 mM Epirubicin for 2 hours. Cell lysates prepared were subjected to immunoblotting with antibodies to pERK, GSK-3b (S9P), pSAPK/JNK and b-actin.
doi:10.1371/journal.pone.0026396.g008
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consequently led to cell death. This hypothesis was supported by
the fact that both AG 1478 and SP 600125 blocked G3 enhanced
expression of Caspase-3 and cell apoptosis while PD 98059 did
not. Reduction in expression of versican and versican G3 domain
by anti-versican siRNA and G3-39UTR construct significantly
reduced G3 enhanced effects on cell apoptosis induced by
chemotherapeutics and confirmed that versican G3-expressing
breast cancer cells promoted cell apoptosis induced by chemo-
therapeutics through G3 dependant mechanisms.
An interesting observation of our study is the apparent dual
roles of versican G3 domain in modulating breast cancer cell
resistance to chemotherapy and EGFR targeting therapy. EGFR
signaling appears crucial to the sensitivity or resistance of versican
expressing breast cancer cells to chemotherapy. The apoptotic
effects of chemotherapeutics on these cells depend on the
activation and balance of EGFR signaling and its effects down-
stream. Certain chemicals such as Doxorubicin and Epirubicin
activate versican G3-expressing cells’ endogenous EGFR/ERK/
GSK-3b (S9P) signaling promoting chemical resistance while
others chemicals appear to enhance these cells’ sensitivity to
chemotherapy through increased expression of EGFR/JNK
signaling and subsequent effects on apoptosis. Our study has
identified a key EGFR down stream proteins, GSK-3b (S9P) that
appears critically important as a regulatory check-point in the
balance of apoptosis and anti-apoptosis (Fig. 8a). Results
demonstrated that G3-expressing cells enhanced GSK-3b (S9P)
expression when treated with a serum free medium, Doxorubicin
or Epirubicin; they also expressed decreased GSK-3b (S9P) and
activated pSAPK/JNK when treated with C2-ceramide or
Docetaxel. The pERK expression remained at high levels when
these cells were treated with different chemicals (Fig. 8b). The
increased expression of GSK-3b (S9P) inhibits the expression of
pSAPK/JNK, enhancing G3-cell survival. Chemicals such as C2-
ceramide and Docetaxel reduce G3-cells expression of GSK-3b
(S9P), which alleviates inhibition of pSAPK/JNK activity
encouraging the survival system favor cell apoptosis. On the other
hand, expression of pSAPK/JNK may also inhibit expression of
GSK-3b (S9P), and enhance cell apoptosis (Fig. 8a). Selective JNK
inhibitor SP 600125 enhanced G3 cells expression of GSK-3b
(S9P) when treated with serum free or C2-ceramide medium
suggesting that expression of pSAPK/JNK inhibits expression of
GSK-3b (S9P), a pathway leading to cell apoptosis (Fig. 2c, Fig. 4c).
A model based on this study of versican G3 modulating breast
cancer cell apoptosis in response to chemotherapy and EGFR
targeting therapy is shown in Fig. 8a.
Although a large number of new agents targeting the EGFR
pathways are being tested and have shown certain efficacy through
greater survival in clinical and pre-clinical models, it remains unclear
as to how combination EGFR therapy with chemotherapy will
impact breast cancer patients. Literature is varied with some clinical
trials demonstrating that EGFR targeting agents synergize with
cytotoxic chemotherapies [59,60], while others have failed to show
any survival advantage of combination over single-agent therapy in
advanced breast cancer patients [58]. These varied effects could
potentially be explained by the interaction of EGFR targeting and
chemotherapeutics on EGFR signaling and effects of cell cycle entry
as well as apoptosis. We have identified that key downstream
pathwayEGFRsignalingproteinssuchasGSK-3b(S9P)may appear
to play a role inhow cellsrespond to treatment.Ongoing study on the
mechanisms of cancer invasiveness and cellular signaling will further
advance our knowledge on how extracellular matrix and cellular
factorssuchasversicanandEGFRsignalingimpactpatientoutcomes
and can be modulated in response to treatment.
Our study has clinical relevance and motivates additional pre-
clinical study towards the development of new clinical agents that
can be tested in the treatment of breast cancer. Our mechanistic
study on EGFR related signaling demonstrates that chemother-
apeutic drugs can have varying effects on signaling that may either
positively or negatively impact cancer cell survival through
mechanisms that influence apoptosis. Although there are several
clinical agents that broadly target EGFR, downstream effects
appear to critically influence cellular apoptosis and the develop-
ment of more specific drugs that can modulate downstream targets
such as GSK-3b (S9P) expression as demonstrated by this study is
desirable. The field of breast cancer chemotherapeutics is also
evolving with recent interest in neoadjuvant approaches to
treatment which serves as a valuable research platform to test
patient specific primary tumor response to systemic therapies prior
to surgery in early disease thereby helping to refine patient
selection for therapy limiting treatment specifically to those that
are most likely to benefit from systemic agents many of which
possess significant toxicity profiles.
Supporting Information
Figure S1 Silencing versican expression using siRNA. a)
MT-1, MDA-MB-231, MCF-7, MDA-MB-468 cell lysates were
subjected to immunoblotting and RT-PCR. b) MT-1 cells were
stably transfected with anti-versican siRNA. Versican V1 expres-
sion was analyzed by immunoblot and RT-PCR. c) The
expression of pERK, ERK, pSAPK/JNK, SAPK/JNK of
vector-expressing and anti-versican siRNA- expressing MT-1 cells
was analyzed by immunoblotting, after treatment with 2 mM
Docetaxel, 8 mM Doxorubicin, or 8 mM Epirubicin for 6 hours. d)
WST-1 assays were used to test cell viability of vector-, versican
G3-transfected, and anti-versican siRNA- transfected MT-1 cells,
which were treated with 40 mM C2-ceramide, 2 mM Docetaxel,
8 mM Doxorubicin, or 10 mM Epirubicin for 24 hours.
(TIF)
Figure S2 Reduction of versican G3’s function using
versican G3-UTR. a) Versican G3 domain was linked with or
without the 39UTR of versican, producing G3 and G3-UTR
constructs. b) Cell lysates prepared from 66c14 cells stably
transfected with versican G3 and G3-UTR construct were
subjected to immunoblotting. c) Vector-transfected, G3-UTR-
transfected, and G3- transfected 66c14 cells (1610
5) were
inoculated in 12 well culture dishes. After culture for 12 hours,
all samples were treated with 40 mM C2-ceramide, 2 mM
Docetaxel, 8 mM Doxorubicin, or 10 mM Epirubicin for 24 hours.
Cell viability was analyzed by light microscopy. d) Vector, G3-
UTR, and G3 transfected 66c14 cells (1610
4) were inoculated and
cultured in 10% FBS/DMEM medium in 96 well culture dishes
for 12 hours. After cell attachment, cells were treated with 40 mM,
C2-ceramide, 2 mM Docetaxel, 8 mM Doxorubicin, or 10 mM
Epirubicin for 24 hours. Cell viability was analyzed by WST-1
assays. Compared with vector control group, n=6, * p,0.05,
**p,0.01, analyzed with t-test.
(TIF)
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